Pharming Group N.V. ADS, each representing 10 ordinary shares
PHAR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$12.02 – $12.55
Volume7,662
Market cap$891M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PHAR.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PHAR.
Recent news
Company coverage with links to the original publishers.
Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference on November 16-19, with management presenting on November 18. The company reported strong revenue growth in Q3 2026 and highlighted the MHRA approval of Joenja® (leniolisib) as the first treatment specifically for children with APDS in the U.K., along with upcoming CVID topline data expected in November.
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of Pharming's Joenja® (leniolisib) to treat children aged 4 to 11 years weighing at least 27kg with activated PI3K delta syndrome (APDS), a rare primary immunodeficiency. This marks the first treatment approved in the U.K. specifically for children with APDS, with availability expected in February 2027. The approval is supported by clinical data from Pharming's pediatric clinical program.
Pharming reported Q3 2026 revenue growth of 21% to $117.6 million with operating profit surging 89% to $29.9 million. The company's core rare disease product RUCONEST stabilized demand, while Joenja accelerated 58% growth through geographic and pediatric expansion. Management is advancing its clinical pipeline into larger immunodeficiency markets with $191 million in cash and no need for external financing.
Pharming Group reported Q1 2026 revenues of US$72.4 million (8% decrease YoY), with RUCONEST® declining 15% due to anticipated inventory drawdowns and market exit, while Joenja® grew 34% YoY. The company resubmitted pediatric sNDA to FDA for Joenja® and received positive CHMP opinion for European approval. Pharming maintained 2026 revenue guidance of US$405-425 million and generated positive operating cash flow of US$2.0 million.
Pharming Group N.V. will report its preliminary Q1 2026 financial results and provide a business update on May 7, 2026, with a conference call and webcast for analysts and investors. The company will also hold its 2026 Annual General Meeting of Shareholders on May 28, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.